GeneDx Holdings Corp. (WGS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Core Viewpoint - GeneDx Holdings Corp. is anticipated to report a year-over-year increase in earnings driven by higher revenues, with a consensus outlook suggesting a significant earnings surprise could impact its stock price in the near term [1][2]. Company Summary - The upcoming earnings report is expected to show quarterly earnings of $0.10 per share, reflecting a year-over-year increase of +190.9%. Revenues are projected to reach $84.7 million, which is a 20.1% increase from the same quarter last year [3]. - The consensus EPS estimate has been revised down by 7.81% over the last 30 days, indicating a reassessment by analysts regarding the company's earnings prospects [4]. - The Most Accurate Estimate for GeneDx Holdings is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +5.26%. The company currently holds a Zacks Rank of 2, suggesting a strong likelihood of beating the consensus EPS estimate [12]. Earnings Surprise History - In the last reported quarter, GeneDx Holdings was expected to post earnings of $0.11 per share but actually delivered earnings of $0.28, resulting in a surprise of +154.55%. The company has beaten consensus EPS estimates in each of the last four quarters [13][14]. Industry Context - In the Zacks Medical Services industry, Revvity is expected to report earnings of $1.14 per share for the quarter ended June 2025, indicating a year-over-year decline of -6.6%. Revenue for Revvity is expected to be $711.27 million, up 2.8% from the previous year [18]. - Revvity's consensus EPS estimate has remained unchanged over the last 30 days, but a higher Most Accurate Estimate has led to an Earnings ESP of +0.88%. This suggests Revvity is also likely to beat the consensus EPS estimate, having done so in each of the trailing four quarters [19].